Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19 - Test2 - elhamkhani - TriplyDB

Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19

Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19

http://www.wikidata.org/entity/Q35211432

about

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy.Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy Pharmacologic studies in vulnerable populations: Using the pediatric experience.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.Using oral agents to manage gestational diabetes: what have we learned?Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations.Pregnancy-related pharmacokinetic changes.Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition.Translational systems pharmacology studies in pregnant women.Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.

P2860

Q28088352-9DC28389-6379-4749-9C03-857D4DD42288 Q28109657-3B676DE6-700E-42CA-80CB-E019E1318AAF Q35214105-FCD6EE01-B187-43C0-8B64-2997FC8BAB87 Q35797203-EF6F3458-4742-41E7-8C3A-6B904C9DFE58 Q36235896-F424C63B-F22B-4092-90C1-8C502542D458 Q36243626-9A24E27E-8622-4707-A02F-21FDCFCD276C Q36683248-56384D61-D241-4D49-AFB9-29A3E7397471 Q37150339-2A1C3C96-DA96-4110-8D13-F0344B2D1E15 Q38332117-B354D26E-FEB4-47B2-80CF-5BFE7EE3409E Q38420688-364C5BB0-8ABE-4901-AC85-6B3C2F1C7DFD Q38661049-7B3DFE53-8181-4A66-9495-C30901E489D5 Q38802632-EAA7120F-A4E8-4BD9-920E-8A24EF379104 Q38809225-4D18ABF4-19B8-4CE5-8BCB-BFF306D9E618 Q41150870-7CCA50E5-FD38-455F-9AA5-D6C0ABCF1CCB Q47271636-5B7D4005-B1C2-40B0-87B8-562E4B6DFE96 Q47312708-53D1396D-AAC2-4B31-9DE4-9AB6AC50F94D Q47724161-B567E764-5055-4174-85EE-ECA96BB085F9 Q47963328-0409EBDA-D306-46B7-8E16-DFC6B1E4DD5E Q47963518-44F3763B-FFFF-4F3E-A0CB-6C5F48651E3B Q48072950-27E3F428-035E-4592-A244-6C3D2549E50F Q50597914-4EE2A97C-723F-4130-8A4E-224A7A161A90 Q50974898-5B41684F-2186-483E-B26A-94A9EBA55336

P2860

Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19

http://www.wikidata.org/entity/Q35211432

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Expansion of a PBPK model to p ...... ing CYP2B6, CYP2C9 and CYP2C19

@ast

Expansion of a PBPK model to p ...... ing CYP2B6, CYP2C9 and CYP2C19

@en

type

label

Expansion of a PBPK model to p ...... ing CYP2B6, CYP2C9 and CYP2C19

@ast

Expansion of a PBPK model to p ...... ing CYP2B6, CYP2C9 and CYP2C19

@en

prefLabel

Expansion of a PBPK model to p ...... ing CYP2B6, CYP2C9 and CYP2C19

@ast

Expansion of a PBPK model to p ...... ing CYP2B6, CYP2C9 and CYP2C19

@en

P1433

Q35211432-33F0DC08-D0DB-471F-8ABD-9E9AD1E2DB57

P1476

Q35211432-4B355B20-0EAD-4288-B7FB-19DFA7A795B6

P2093

Q35211432-0BEFD454-626C-4C43-9C11-653A3BEE943F

Q35211432-1D80FFDF-985D-4C6E-9A90-9719ECFD62B8

Q35211432-20B11D6E-B372-4136-B76F-713A7C5BB4BC

Q35211432-7D86D742-E60B-45A3-9015-7AA3BA297D5C

Q35211432-96EA71A4-C46D-4837-9843-D67815CB86EE

P2860

Q35211432-06EECB93-E3E3-4B46-A707-21BA67850162

Q35211432-08AED4BC-2796-4694-A57A-FA2D197C171B

Q35211432-0D69EF0E-689F-4045-94C0-8B4C0D3ADF4A

Q35211432-0DDD59B7-54B2-4AC8-A36D-DF1C779DDB15

Q35211432-0EB6FA66-EE3E-4912-8393-FE565CF29DAC

Q35211432-18455C50-7D11-4AB0-BCC0-613E172EABE1

Q35211432-2305E706-20F0-4145-ACB3-AB16B8B4C955

Q35211432-2AA6E0A6-8587-49D5-A1BA-C99FE3485773

Q35211432-2CD15C7A-ADF3-4F06-819F-8EB8C8A6A4CE

Q35211432-2ECBCB01-78C8-45AB-9F89-E7420A5E27FD

P304

Q35211432-8CCB02B7-86E0-430A-99FE-726797861D71

P31

Q35211432-29674AFC-1C04-4DA2-B0DD-10857EC96EDF

P356

Q35211432-83987398-C674-4FC2-971F-FD32C72F561C

P407

Q35211432-EC6D4C7C-959C-4C48-A0AA-09B83FCD89C2

P433

Q35211432-60301CE7-3CB8-45D8-8738-74F2D71FB890

P478

Q35211432-B32D8D58-2BC3-49C3-A701-CDF16F5690A2

P577

Q35211432-59EB7790-F6D9-4406-AE66-6BDB1FDC04D8

P698

Q35211432-4EE90392-1DDD-4326-9C32-A301CF26E45C

P932

Q35211432-DB1315C1-01A3-4847-B24E-8BD44D0778D4

P356

P1433

British Journal of Clinical Pharmacology

P1476

Expansion of a PBPK model to p ...... ing CYP2B6, CYP2C9 and CYP2C19

@en

P2093

Alice Ban Ke

http://www.w3.org/2001/XMLSchema#string

Amin Rostami-Hodjegan

http://www.w3.org/2001/XMLSchema#string

Jashvant D Unadkat

http://www.w3.org/2001/XMLSchema#string

Ping Zhao

http://www.w3.org/2001/XMLSchema#string

Srikanth C Nallani

http://www.w3.org/2001/XMLSchema#string

P2860

Drug interactions with clinafloxacin.

Methadone: a review of its pharmacokinetic/pharmacodynamic properties.

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone.

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

Enantiomeric metabolic interactions and stereoselective human methadone metabolism.

Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

Prediction of intestinal first-pass drug metabolism.

Contributions of human cytochrome P450 enzymes to glyburide metabolism.

P304

554-570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12207

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23834474

http://www.w3.org/2001/XMLSchema#string

P932

4371535

http://www.w3.org/2001/XMLSchema#string